BULGOLD Provides an Update on the Lutila Gold Project
TORONTO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- BULGOLD Inc. (TSXV: ZLTO) (the “Company” or “BULGOLD”) is pleased to provide a progress update on its Lutila Gold Project located in Central…
Verses AI Inc. Announces LIFE Private Placement Offering up to C$10,000,000
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Verses AI Inc. (CBOE:…
Mobile-health Network Solutions Delinquency Notification Letter From Nasdaq
SINGAPORE, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) ("MaNaDr" or "the Company"), a leading Asia-Pacific telehealth provider, today announced that it received a notice dated September…
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant Approval based on…
Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué (…)
Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué, non éligibles à une transplantation Approbation fondée…
Bunker Hill Announces Election to Issue Shares in Satisfaction of Debenture Interest Payment Obligations
VANCOUVER, British Columbia, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Bunker Hill Mining Corp. (“Bunker Hill” or the “Company”) (TSX-V: BNKR; OTCQB: BHILL) announces that it has elected to issue an…
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific and clinical advances that support optimal treatment options and decisions…
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-‘749Currently, there is no long-acting olanzapine treatment…
Man Group PLC : Form 8.3
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a)…
Kaldalón hf.: Staðfesting á skýrslu um fjárhagsleg- og sérstök skilyrði
KPMG er staðfestingaraðili vegna almenns tryggingafyrirkomulags Kaldalóns hf. KPMG hefur nú framkvæmt könnun á útreikningum útgefanda á fjárhagslegum og sérstökum skilyrðum skuldabréfa undir almenna tryggingafyrirkomulaginu. Niðurstaða KPMG staðfestir að fjárhagsleg…